NGFR and neoplasm: When 1,000 cells were injected, the control cells formed tumors at seven out of eight sites (7/8), whereas the CD271-knockdown cells (#1) formed tumors at three out of four sites (3/4) and the CD271-knockdown cells (#2) formed no tumor at any of four sites, 5 weeks after the xenograft.